About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our main research aims at understanding the molecular basis of hereditary disease, integrating two complementary aspects: the molecular impact of genetic variants and the regulatory role of genetic background. At a technical level, to reach our objective, we integrate the results of the most advanced genomic experiments (single-cell RNAsq, NGS sequencing, etc.) using state-of-the-art machine learning tools.
As a result of our efforts, we have recently made significant advances in understanding the functional effect of BRCA1/2 protein variants underlying hereditary breast and ovarian cancers. In fact, the methodology developed earned us the second position in the group classification at the international competition CAGI 5, held in 2019.
PMID: 33280026 Journal: CLINICAL CHEMISTRY Year: 2021 Reference: Clin Chem. 2021 Mar 1;67(3):518-533. doi: 10.1093/clinchem/hvaa250. Impact factor: Publication type: Paper in international publication Authors: Blanco, Ana; Capella, Gabriel; de la Cruz, Xavier; de la Hoya, Miguel; Diez, Orland; Feliubadalo, Lidia; Gutierrez-Enriquez, Sara; Lazaro, Conxi; Lopez-Novo, Anael; Moles-Fernandez, Alejandro et al. DOI: 10.1093/clinchem/hvaa250
PMID: 30934865 Journal: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Year: 2019 Reference: Int J Mol Sci. 2019 Mar 29;20(7). pii: ijms20071583. doi: 10.3390/ijms20071583. Impact factor: Publication type: Paper in international publication Authors: Aguirre, Josu; de la Cruz, Xavier; Fernandez-Recio, Juan; Navio, Damaris; Rosell, Mireia et al. DOI: 10.3390/ijms20071583
PMID: 30568281 Journal: NEUROPSYCHOPHARMACOLOGY Year: 2019 Reference: Neuropsychopharmacology. 2019 Apr;44(5):890-897. doi: 10.1038/s41386-018-0297-0. Epub 2018 Dec 19. Impact factor: Publication type: Paper in international publication Authors: Arias-Vasquez, Alejandro; Artigas, Maria Soler; Casas, Miguel; Corrales, Montse; de la Cruz, Xavier; Fadeuilhe, Christian; Franke, Barbara; Garcia-Martinez, Iris; Padilla, Natalia; Pagerols, Mireia et al. DOI: 10.1038/s41386-018-0297-0
PMID: 30848931 Journal: FASEB JOURNAL Year: 2019 Reference: FASEB J. 2019 Jun;33(6):7168-7179. doi: 10.1096/fj.201801591R. Epub 2019 Mar 8. Impact factor: Publication type: Paper in international publication Authors: Aguirre, Josu; Blazquez-Bermejo, Cora; Cabrera-Perez, Raquel; Camara, Yolanda; Carreno-Gago, Lidia; de la Cruz, Xavier; Dominguez-Gonzalez, Cristina; Garcia-Arumi, Elena; Lombes, Anne; Marti, Ramon et al. DOI: 10.1096/fj.201801591R
PMID: 31294896 Journal: HUMAN MUTATION Year: 2019 Reference: Hum Mutat. 2019 Sep;40(9):1546-1556. doi: 10.1002/humu.23861. Epub 2019 Aug 23. Impact factor: 4.453 Publication type: Paper in international publication Authors: Shen, Yang, Sun, Yuanfei, Topper, Scott, Parsons, Michael T, Spurdle, Amanda B, Goldgar, David E, Savojardo, Castrense, Riera, Casandra, Radivojac, Predrag, Pejaver, Vikas et al. DOI: 10.1002/humu.23861
PMID: 28453649 Journal: NUCLEIC ACIDS RESEARCH Year: 2017 Reference: Nucleic Acids Res. 2017 Jul 3;45(W1):W222-W228. doi: 10.1093/nar/gkx313. Impact factor: Publication type: Paper in international publication Authors: de la Cruz, Xavier; Gazzo, Andrea; Gelpi, Josep Ll; Lopez-Ferrando, Victor; Orozco, Modesto et al. DOI: 10.1093/nar/gkx313
PMID: 28365877 Journal: Familial Cancer Year: 2017 Reference: Fam Cancer. 2017 Oct;16(4):501-507. doi: 10.1007/s10689-017-9981-1. Impact factor: Publication type: Paper in international publication Authors: Balaguer, Francesc; Cadinanos, Juan; Capella, Gabriel; Cuesta, Raquel; de la Cruz, Xavier; Del Valle, Jesus; Fernandez, Anna; Gonzalez-Acosta, Maribel; Iglesias, Silvia; Lazaro, Conxi et al. DOI: 10.1007/s10689-017-9981-1
The Clinical and Translational Bioinformatics Group at VHIR has been responsible for the computational analysis of two international genetic studies led by the Children's Hospital of Philadelphia.
The Clinical and Translational Bioinformatics group is launching the project to use cutting-edge artificial intelligence in the identification of pathogenic variants.
